Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders’ Equity listing requirements and Hearing to Present a Plan for Regaining Compliance
JERUSALEM, May 24, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (the "Company") (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and...